Advertisement
HomeCollectionsBolar
IN THE NEWS

Bolar

FIND MORE STORIES ABOUT:
FEATURED ARTICLES
NEWS
November 13, 2006
On November 10, 2006, CARL BOLAR; beloved husband of Helena Bolar; devoted father of three sons, Carl, Jr., Carlin and Keith; stepdaughter, Helena Pope; two step-sons, Donald and William Goodin; one grandchild, Dominique Bolar; two sisters, Clarice Reid and Sylvia Culley; one daughter-in-law, Joyce Bolar; one sister-in-law, Elaine Fenderson and a host of relatives and friends. On Tuesday friends may call at the VAUGHN C. GREENE FUNERAL SERVICES, 5151 Balto. Nat'l. Pike from 3:00-8:00 P.M. On Wednesday, Mr. Bolar will lie instate at Christ Edmondson U. M. C., 3600 Edmondson Avenue, where the family will receive friends from 11:30.
ARTICLES BY DATE
NEWS
November 13, 2006
On November 10, 2006, CARL BOLAR; beloved husband of Helena Bolar; devoted father of three sons, Carl, Jr., Carlin and Keith; stepdaughter, Helena Pope; two step-sons, Donald and William Goodin; one grandchild, Dominique Bolar; two sisters, Clarice Reid and Sylvia Culley; one daughter-in-law, Joyce Bolar; one sister-in-law, Elaine Fenderson and a host of relatives and friends. On Tuesday friends may call at the VAUGHN C. GREENE FUNERAL SERVICES, 5151 Balto. Nat'l. Pike from 3:00-8:00 P.M. On Wednesday, Mr. Bolar will lie instate at Christ Edmondson U. M. C., 3600 Edmondson Avenue, where the family will receive friends from 11:30.
Advertisement
BUSINESS
By Kelly Gilbert and Kelly Gilbert,Evening Sun Staff | February 7, 1991
Bolar Pharmaceutical Co.'s former director of regulatory affairs has pleaded guilty to federal criminal charges for lying to the U.S. Food and Drug Administration and falsifying company records to obstruct an FDA inspection.Susan M. Long, 44, of Long Island, N.Y., entered guilty pleas Tuesday to false statement and obstruction charges before Judge John R. Hargrove in U.S. District Court in Baltimore. The judge set sentencing for June 14.Long is the 17th defendant to plead guilty to criminal charges in a 2 1/2 -year probe centered in the U.S. attorney's office here, and the third Bolar official convicted of charges tied to the company's manufacture of Triamterene Hydrochlorothiazide, a generic hypertension drug.
NEWS
By Norris P. West and Norris P. West,Staff Writer | January 23, 1993
A federal judge yesterday sentenced the former head of a drug company to five years in jail and a $1.25 million fine -- the largest penalty against an individual since the government began investigating generic drug fraud four years ago.Judge John R. Hargrove imposed the sentence upon Robert Shulman, 59, of Centerport, N.Y., for filing false statements to gain approval for products made by Bolar Pharmaceutical Inc. of Copiague, N.Y.The sentence, handed down...
BUSINESS
By Kelly Gilbert and Kelly Gilbert,Evening Sun Staff | December 13, 1990
Bolar Pharmaceutical Co.'s former regulatory affairs manager has pleaded guilty to federal criminal charges for rigging tests of a lucrative generic hypertension drug so the U.S. Food and Drug Administration would approve it for public sale.The defendant, Gloria H. Schetlick, pleaded guilty in U.S. District Court in Baltimore yesterday to false statement and obstruction of justice charges.Prosecutors alleged that Schetlick mislabeled Bolar drug samples so they would pass FDA-required "bioequivalency" tests, submitted the bogus test results to the FDA for approvals and lied to agency officials in a later attempt to hide the test rigging.
NEWS
By M. Dion Thompson | October 18, 1990
A former high-level employee of the Bolar Pharmaceutical Co. Inc. has been charged with obstructing the U.S. Food and Drug Administration's investigation of the company, federal prosecutors said yesterday.Gena R. Finelli, who is to be arraigned in U.S. District Court in Baltimore on Oct. 23, was director of Bolar's research and development laboratory. She was named in a one-count criminal charge and has agreed to cooperate with the government's investigation.According to Gary P. Jordan, first assistant U.S. attorney, FDA officials in Rockville asked their counterparts in New York last year to inspect Bolar for possible violations of the Food and Drug Act. While inspecting the company, which is based in Long Island, N.Y., FDA officials allegedly asked to talk to laboratory chemists who worked for Ms. Finelli.
NEWS
By Sheridan Lyons | March 23, 1991
Bolar Pharmaceutical Co. Inc. was fined a a record $10 million yesterday after pleading guilty to putting untested generic drugs on the market by falsifying tests, then destroying evidence and lying to the Food and Drug Administration, a federal grand jury and Congress.The penalty, issued in U.S. District Court, is the largest criminal fine ever imposed in the District of Maryland, said First Assistant U.S. Attorney Gary P. Jordan.Bolar, of Copiague, N.Y., the largest publicly held generic drug company in the United States, has dismissed officials from the president on down in a broad purge, according to the company's attorney, William C. Hendricks III, and its new executive vice president and general counsel, Jack J. Kornreich.
BUSINESS
By Kelly Gilbert and Kelly Gilbert,Evening Sun Staff | November 8, 1991
Robert Shulman, Bolar Pharmaceutical Inc.'s former president, chief executive and board chairman, has pleaded guilty to conspiracy, obstruction of justice and other charges tied to fraud in the company's generic-drug operation.First Assistant U.S. Attorney Gary P. Jordan said in U.S. District Court in Baltimore yesterday that Shulman also has agreed to plead guilty to an unspecified antitrust violation to be filed here soon by the U.S. Department of Justice.Lawrence G. McDade, assistant director of the Justice Department's consumer litigation office, told Judge John R. Hargrove yesterday that Shulman and Jacob H. "Jack" Rivers, Bolar's former executive vice president, masterminded the company's massive fraud to skirt federal procedures in the manufacture and sale of its highly profitable products for six years.
BUSINESS
By Kelly Gilbert and Kelly Gilbert,Evening Sun Staff | June 19, 1991
PharmaKinetics Laboratories Inc. and its former vice president have pleaded guilty to obstructing a federal investigation of Bolar Pharmaceutical Co., a generic drug company that itself has been convicted of a corruption charge.Judge John R. Hargrove accepted the pleas in U.S. District Court in Baltimore yesterday and fined PharmaKinetics $200,000, an amount recommended by federal prosecutors.Mark B. Perkal, a PharmaKinetics founder and former executive vice president, pleaded guilty at a separate hearing yesterday.
NEWS
By Kelly Gilbert and Kelly Gilbert,Evening Sun Staff | October 11, 1991
Bolar Pharmaceutical Inc.'s former president, executive vice president and two other high-ranking officials have been charged with conspiracy and related counts tied to at least six years of corruption in the company's manufacture of generic drugs.The four were charged yesterday in a five-count criminal information document and a 19-count indictment filed in U.S. District Court in Baltimore by a grand jury and prosecutors in a federal generic drug task force based here.Each of the defendants is charged with conspiring to "evade, defeat and obstruct" the U.S. Food and Drug Administration's generic drug approval process, from at least February 1984 to early 1990.
NEWS
July 29, 1992
People entrusted to check the safety and efficacy of pharmaceuticals occupy a special place in our society. We put our health and our lives in their hands. When they violate this trust, they deserve severe punishment. The sentence received last week by Mark B. Perkal, the former chief scientific officer and executive vice president of PharmaKinetics Laboratories, does not come close to punishing him for his transgressions.Perkal supervised the operations of PharmaKinetics, a Baltimore company that tests the effects of newly developed drugs on human subjects.
NEWS
By Norris P. West and Norris P. West,Staff Writer | July 23, 1992
As Mark Perkal stood before a judge yesterday to be sentenced in a generic drug scam, he did not stand alone. His family and members of Baltimore's Hasidic community stood with him.While seven witnesses, including his wife and daughter, testified that Perkal was a pillar of the community and a religious man with the highest moral values, 100 more supporters jammed Judge John R. Hargrove's U.S. District Courtroom and overflowed into the lobby.That outpouring of support apparently worked.Judge Hargrove sentenced Perkal, 46, of the 3800 block of Labyrinth Road, to four months of the least restrictive form of home detention on his guilty plea to charges of obstruction of justice and aiding and abetting false statements to the U.S. Food and Drug Administration.
NEWS
By Norris P. West and Norris P. West,Staff Writer | April 16, 1992
In last Thursday's editions, the disposition of a U.S. District Court case involving PharmaKinetics Laboratories of Baltimore was incorrectly reported.PharmaKinetics itself was fined $200,000 in June after pleading guilty to obstructing an agency proceeding -- a Food and Drug Administration investigation involving generic drug testing and certification.The company's former executive vice president, Mark B. Perkal, is awaiting sentencing for his guilty plea to obstruction and aiding and abetting charges.
BUSINESS
By Liz Bowie and Liz Bowie,Staff Writer | March 19, 1992
PharmaKinetics Laboratories Inc., said yesterday that it plans to sell off its German subsidiary as part of a restructuring to help it emerge from Chapter 11 bankruptcy protection.Under the terms of the sale, PharmaKinetics would receive $1.95 million in cash and $1.4 million in common shares of TSI Corp., a Worcester, Mass., company that will purchase the PharmaKinetics subsidiary, International Bio Research. TSI and International Bio Research both test drugs and cosmetics on animals before human trials.
BUSINESS
By Kelly Gilbert and Kelly Gilbert,Evening Sun Staff | November 8, 1991
Robert Shulman, Bolar Pharmaceutical Inc.'s former president, chief executive and board chairman, has pleaded guilty to conspiracy, obstruction of justice and other charges tied to fraud in the company's generic-drug operation.First Assistant U.S. Attorney Gary P. Jordan said in U.S. District Court in Baltimore yesterday that Shulman also has agreed to plead guilty to an unspecified antitrust violation to be filed here soon by the U.S. Department of Justice.Lawrence G. McDade, assistant director of the Justice Department's consumer litigation office, told Judge John R. Hargrove yesterday that Shulman and Jacob H. "Jack" Rivers, Bolar's former executive vice president, masterminded the company's massive fraud to skirt federal procedures in the manufacture and sale of its highly profitable products for six years.
NEWS
By Kelly Gilbert and Kelly Gilbert,Evening Sun Staff | October 11, 1991
Bolar Pharmaceutical Inc.'s former president, executive vice president and two other high-ranking officials have been charged with conspiracy and related counts tied to at least six years of corruption in the company's manufacture of generic drugs.The four were charged yesterday in a five-count criminal information document and a 19-count indictment filed in U.S. District Court in Baltimore by a grand jury and prosecutors in a federal generic drug task force based here.Each of the defendants is charged with conspiring to "evade, defeat and obstruct" the U.S. Food and Drug Administration's generic drug approval process, from at least February 1984 to early 1990.
BUSINESS
By Kelly Gilbert and Kelly Gilbert,Evening Sun Staff | June 18, 1991
Baltimore-based PharmaKinetics Laboratories Inc. pleaded guilty today to obstructing a federal generic drug investigation, and was fined $200,000 by the judge who accepted the plea.Mark B. Perkal, a PharmaKinetics founder and the firm's former executive vice president, also pleaded guilty to an obstruction charge today at a separate hearing in U.S. District Court in Baltimore.Perkal and defense attorney William A. McDaniel Jr. said in court that two senior Bolar Pharmaceutical Co. officials threatened Perkal's life and the lives of his family if he did not help them cover up a Bolar drug-switching scheme during investigations that led to the criminal charges.
NEWS
By Kelly Gilbert and Kelly Gilbert,Evening Sun Staff | October 8, 1991
Two former officials of generic drug companies have pleaded guilty in federal court to criminal charges for falsifying records to hide deficiencies in products approved for sales to the public in the late 1980s.Juan Manuel Rodriguez, 61, former product development manager at Bolar Pharmaceutical Co., pleaded guilty in U.S. District Court here last Thursday to a charge of attempting to obstruct a U.S. Food and Drug Administration investigation of RTC the Copiague, N.Y., company regarding its then-popular Triamterene-Hydrochlorothiazide, a generic hypertension medicine.
BUSINESS
By Jon Morgan and Jon Morgan,Evening Sun Staff Kelly Gilbert contributed to this story | October 2, 1991
A Sykesville woman who suffered liver damage after taking a drug has sued its manufacturer and the Baltimore testing laboratory that she claims fraudulently conspired to have the drug sold as a generic equivalent of the blood-pressure medicine her doctor prescribed.Veleria Wilkins, 42, claims to have suffered permanent and disabling injuries after taking Triamterene/Hydrochlorothiazide manufactured by Bolar Pharmaceutical Co. of Copaigue, N.Y.She is suing Bolar and Pharmakinetics Laboratories of Baltimore as well as Mark B. Perkal, a Pharmakinetics founder and former official.
Baltimore Sun Articles
|
|
|
Please note the green-lined linked article text has been applied commercially without any involvement from our newsroom editors, reporters or any other editorial staff.